CTOs on the Move

Enliven Therapeutics

www.enliventherapeutics.com

 
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

RHEI Pharmaceuticals

RHEI Pharmaceuticals is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blissco

BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) is an ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships. BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets. BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo`s future patients and customers.

Vilex

Vilex is an innovative manufacturer of orthopaedic internal and external fixation devices, plates, and small joint implants.

Galleon Pharmaceutical

Galleon Pharmaceutical is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ohr Pharmaceutical

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.